Oppenheimer Assumes ESSA Pharma at Outperform, Announces Price Target of $17
Portfolio Pulse from richadhand@benzinga.com
Oppenheimer analyst Mark Breidenbach assumes ESSA Pharma (NASDAQ:EPIX) with an Outperform rating and announces a price target of $17.
June 26, 2023 | 10:48 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer assumes ESSA Pharma with an Outperform rating and a price target of $17.
The Outperform rating and $17 price target by Oppenheimer analyst Mark Breidenbach indicate a positive outlook for ESSA Pharma's stock. This news is likely to attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100